Latest News

The biosimilars can be used to treat osteoporosis- and cancer-related bone loss in certain populations.

The program’s legitimacy rests on transparency, audits, and ensuring benefits reach vulnerable patients.

The research further emphasizes the need for more attention on both chronic kidney disease (CKD) and mental health conditions.

New RSV vaccines for older adults enhance prevention efforts, yet awareness and uptake remain low. Pharmacists play a crucial role in improving vaccination rates.

Natural strategies and OTC options can help manage menopause symptoms, from hot flashes to mood changes, for a smoother transition.

The approval is based on results from the phase 3 DeLLphi-304 clinical trial.

FDA approves daratumumab and hyaluronidase for treating newly diagnosed light chain (AL) amyloidosis, enhancing survival rates and treatment efficacy.

The FDA accelerates approval of sevabertinib for advanced non–small cell lung cancer, showcasing promising efficacy and manageable safety in clinical trials.

Selumetinib gains FDA approval for adults with neurofibromatosis type 1, offering hope for those with inoperable plexiform neurofibromas.

Measles resurges globally, threatening U.S. elimination status; pharmacists play a crucial role in vaccination efforts and outbreak response.

An evaluation of the different dosing and administration regimens of high-dose nitroglycerin for sympathetic crashing acute pulmonary edema.

Guselkumab and paltusotine received FDA approval, Kenvue announced the new Tylenol Precise Pain-Relieving Patch, and a new generic version of mifepristone received the green light from the FDA.

Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.

Elinzanetant Showed Smaller Reductions in Bone Mineral Density Than Placebo

Routine multicancer early detection tests significantly improve early cancer diagnoses, reducing late-stage cases and enhancing treatment outcomes.

With this action, Thrombate III has become the first and only antithrombin concentrate approved for adult and pediatric patients with hereditary antithrombin deficiency (hATd).

Plozasiran gains FDA approval to significantly lower triglycerides in adults with familial chylomicronemia syndrome, enhancing heart health management.

Amoxicillin is a favorable choice for outpatient use in pediatric patients given its relatively narrow spectrum of activity and palatable formulation.

Epcoritamab-bysp demonstrated impressive response rates and improved progression-free survival.

The Annual Meeting Highlighted Emerging Research on Hormone Therapy, Brain and Heart Health, Disparities in Menopause Care, and the Expanding Role of Pharmacists